Amgen Inc.

Japan Tobacco Inc.

Shinji Yata

Jay Patrick Powers

Makoto Kakutani

Hiroyuki Goto

Yasuhiro Ohe

Mario G Cardozo

Yoshikazu Hori

Yoshihisa Koga

Wataru Kondo

Takayuki Yamasaki

Katsuaki Imamura

Hiroyuki Abe

Koji Kobayashi

Takuya Matsuo

Itsuo Uchida

Masahiro Sakata

Isamu Matsuda

Kazuhito Harada

Takashi Watanabe

Minoru Akamatsu

Hua Tu

Tatsuya Matsumoto

Jun Nishiu

Hidekazu Ozeki

Katsuo Toide

Motohiro Kogayu

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.

Triazole compounds and uses related thereto

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt: 

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR; Ris a hydrogen atom or a halogen atom; Ris a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and Ris a halogen atom. However, Ris a halogen atom when X is CR). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc. 

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome. 

Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.

Pyrazole compounds and uses related thereto

Compound having prolyl endopeptidase inhibitory activity and

Growing community of inventors

Takatsuki, Japan

Shinji Yata